How does Montelukast improve breathing?

Montelukast improves breathing primarily by decreasing the inflammatory response in the airways. It is a leukotriene receptor antagonist, which means that it blocks the action of leukotrienes—substances in the body that contribute to inflammation in conditions like asthma and allergies. By inhibiting these mediators, Montelukast reduces airway swelling and mucus production, making it easier for individuals to breathe. This action helps to alleviate symptoms such as wheezing, shortness of breath, and coughing, thus enhancing overall respiratory function.

The other options suggest mechanisms that do not accurately reflect how Montelukast works. For instance, increasing mucus production would typically lead to airway obstruction rather than improved breathing. Directly opening airways is closer to the action of bronchodilators, which Montelukast is not. Inhibiting the cough reflex does not directly address the underlying inflammation that Montelukast targets, although it might help with symptom relief in other contexts. Therefore, the focus on decreasing inflammation aligns with the primary therapeutic benefit of Montelukast in managing breathing difficulties associated with asthma and allergic reactions.